14678-93-4

Basic information

• Product Name: 5-AMINO-1-(4-METHYLPHENYL)-1H-PYRAZOLE-&
• Synonyms: 5-AMINO-1-(4-METHYLPHENYL)-1H-PYRAZOLE-&;5-Amino-1-(4-methylphenyl)-1H-pyrazole-4-carboxylic acid 97%
• CAS NO: 14678-93-4
• Molecular Formula: C₁₁H₁₁N₃O₂
• Molecular Weight: 217.23
• Product Categories: Building Blocks;Heterocyclic Building Blocks;Pyrazoles
• Mol File: 14678-93-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 182-186 °C(lit.)
• Boiling Point: 435.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• PKA: 4.49±0.10(Predicted)
• CAS DataBase Reference: 5-AMINO-1-(4-METHYLPHENYL)-1H-PYRAZOLE-&(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-1-(4-METHYLPHENYL)-1H-PYRAZOLE-&(14678-93-4)
• EPA Substance Registry System: 5-AMINO-1-(4-METHYLPHENYL)-1H-PYRAZOLE-&(14678-93-4)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 14678-93-4(Hazardous Substances Data)

Usage

General Description

5-Amino-1-(4-methylphenyl)-1H-pyrazole is a chemical compound with the molecular formula C10H11N3. It is a pyrazole derivative that contains an amino group and a 4-methylphenyl group. The compound is used in pharmaceutical research and drug development as a building block in the synthesis of various biologically active compounds. It has been studied for its potential therapeutic applications, particularly as an antitumor agent and a potential treatment for various neurological conditions. The compound's structure and properties make it a valuable tool for researchers studying the development of new drugs and therapies for a range of medical conditions.

Upstream product

• 539-44-6 N-4-methylphenylhydrazine 
• 637-60-5 p-tolylhydrazine hydrochloride 
• 15001-11-3 ethyl 5-amino-1-(p-tolyl)-1H-pyrazole-4-carboxylate 

Relevant articles and documents

Novel Pyrazolo[3,4- d]pyrimidin-4-one Derivatives as Potential Antifungal Agents: Design, Synthesis, and Biological Evaluation

Plant pathogenic fungi seriously threaten agricultural production. There is an urgent need to develop novel fungicides with low toxicity and high efficiency. In this study, we designed and synthesized 44 pyrazolo[3,4-d]pyrimidin-4-one derivatives and evaluated them for their fungicidal activities. The bioassay data revealed that most of the target compounds possessed moderate to high in vitro antifungal activities. Especially compound g22 exhibited remarkable antifungal activity against Sclerotinia sclerotiorum with an EC50 value of 1.25 mg/L, close to that of commercial fungicide boscalid (EC50 = 0.96 mg/L) and fluopyram (EC50 = 1.91 mg/L). Moreover, compound g22 possessed prominent protective activity against S. sclerotiorum in vivo for 24 h (95.23%) and 48 h (93.78%), comparable to positive control boscalid (24 h (96.63%); 48 h (93.23%)). Subsequent studies indicated that compound g22 may impede the growth and reproduction of S. sclerotiorum by affecting the morphology of mycelium, destroying cell membrane integrity, and increasing cell membrane permeability. In addition, the application of compound g22 did not injure the growth or reproduction of Italian bees. This study revealed that compound g22 is expected to be developed for efficient and safe agricultural fungicides.

Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity

The identification of novel Topoisomerase II (Topo II) inhibitors is one of the most attractive directions in the field of bactericide research and development. In our ongoing efforts to pursue the class of inhibitors, six series of 70 novel coumarin-pyrazole carboxamide derivatives were designed and synthesized. As a result of the evaluation against four destructive bacteria, including Staphylococcus aureus, Listeria monocytogenes, Escherichia coli and Salmonella. Compound 8III-k (MIC = 0.25 mg/L) showed considerable inhibitory activity than ciprofloxacin (MIC = 0.5 mg/L) against Escherichia coli and 8V-c (MIC = 0.05 mg/L) exhibited excellent antibacterial activity than ciprofloxacin (MIC = 0.25 mg/L) against Salmonella. The selected compounds (8III-k, 8V-c and 8V-k) exhibit potent inhibition against Topo II and Topo IV with IC50 values (9.4–25 mg/L). Molecular docking model showed that the compounds 8V-c and 8V-k can bind well to the target by interacting with amino acid residues. It will provide some valuable information for the commercial Topo II inhibiting bactericides.